Pharmala Biotech Holdings Inc. MDMA
CNSX
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 920.60K | 643.10K | 540.70K | 434.50K | 300.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 920.60K | 643.10K | 540.70K | 434.50K | 300.00K |
| Cost of Revenue | 193.30K | 72.90K | 63.20K | 38.20K | -95.50K |
| Gross Profit | 727.30K | 570.20K | 477.40K | 396.20K | 395.40K |
| SG&A Expenses | 1.55M | 1.37M | 1.57M | 1.57M | 1.46M |
| Depreciation & Amortization | 86.10K | 84.90K | 83.60K | 83.80K | 79.20K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.95M | 1.68M | 1.90M | 1.87M | 1.64M |
| Operating Income | -1.03M | -1.03M | -1.36M | -1.43M | -1.34M |
| Income Before Tax | -1.17M | -1.18M | -1.50M | -1.55M | -1.45M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.17 | -1.18 | -1.50 | -1.55 | -1.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.17M | -1.18M | -1.50M | -1.55M | -1.45M |
| EBIT | -1.03M | -1.03M | -1.36M | -1.43M | -1.34M |
| EBITDA | -991.00K | -984.40K | -1.30M | -1.36M | -1.28M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 424.99M | 421.23M | 414.11M | 398.18M | 390.88M |
| Average Diluted Shares Outstanding | 424.99M | 421.23M | 414.11M | 398.18M | 390.88M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |